Subscribe to The Insides™ Company Newsletter
Stay up-to date & receive our latest news
The Insides™ System has been granted Breakthrough Device Designation by the US FDA as it addresses a high unmet clinical need.
The Insides™ System is now commercially available in the United Kingdom, Europe and New Zealand after being CE-marked and registered on the New Zealand MedSafe WAND database.
*The Insides™ System is not available in other markets.
*The Insides™ System is not available in other markets.
Chyme Reinfusion is recommended by the European Society of Clinical Nutrition and Metabolism (ESPEN) and American Society for Parenteral and Enteral Nutrition (ASPEN) for the nutrition in patients with acute intestinal failure.
The existing literature also favours chyme reinfusion for its ability to restore intestinal continuity, and improve intestinal function, hydration and the nutritional status of the patient. The benefits of chyme reinfusion improves recovery and conditions patients for definitive surgery.
The Insides™ System enables patients to recommence oral feeding and wean off the expensive therapy of parenteral nutrition. This reduces their length of stay in hospital and potential complications.
Connects magnetically to The Insides™ Pump via the outside of the patient's ostomy appliance whenever the patient needs to power the pump and refeed the content of the ostomy appliance back into their distal intestine.
*The Insides™ System is not available in other markets.
Sits within the ostomy appliance, and pumps the chyme into the distal intestine via The Insides™ Tube
Inserted into the distal intestine and connected to The Insides™ Pump, serving as a conduit for chyme
Professor
Greg O’Grady
Co-Founder & Chief Scientific Officer
“Chyme refeeding reduces recovery time, while minimising harms attributed to a defunctioned colon.”
The Insides™ System has been developed on the back of 30+ years of clinical experience in gut nutrition, along with research and development from one of Australasia’s top Universities.
Professor Ian Bissett
Co-Founder & Chief Medical Officer
.png){kind=small}
.png){kind=small}
